

Drug resistance interpretation: PR

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

None

None

L10I 10%
seen:3,137 • T12I 10%
seen:3,140 • I13V 10%
seen:3,141 • K14R 10%
seen:3,147 • G16E 10%
seen:3,183 • E35D 10%
seen:3,214 • M36I 100%
seen:5,214 • R41K 10%
seen:5,229 • R57K 10%
seen:4,585 • L63S 10%
seen:4,152 • H69K 10%
seen:3,247 • K70R 10%
seen:3,247 • I72IV 1.73%
seen:3,711 • L89M 100%
seen:3,752

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

- L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

K219Q 17%
seen:505

Y181C 10%
seen:2,892

ISIV 1.10%
seen:3,117 • V35T 10%
seen:2,885 • T39KN 1.10%
seen:2,540 • K43KE 1.12%
seen:2,540 • V60I 10%
seen:3,361 • V90I 10%
seen:3,397 • K122E 100%
seen:2,200 • D123S 100%
seen:2,391 • I142V 17%
seen:2,514 • S162Y 17%
seen:2,540 • K173S 100%
seen:2,304 • Q174K 100%
seen:2,304 • D177E 10%
seen:2,305 • V179I 10%
seen:2,305 • T200A 100%
seen:1,980 • Q207A 100%
seen:1,540 • R211S 10%
seen:1,574 • F214L 100%
seen:492 • L228R 100%
seen:472

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Susceptible

zidovudine (AZT)

Potential Low-Level Resistance

stavudine (D4T)

Potential Low-Level Resistance

didanosine (DDI)

Susceptible

emtricitabine (FTC)

Susceptible

lamivudine (3TC)

Susceptible

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

Potential Low-Level Resistance

efavirenz (EFV)

Intermediate Resistance

etravirine (ETR)

Intermediate Resistance

nevirapine (NVP)

High-Level Resistance

rilpivirine (RPV)

Intermediate Resistance

RT comments

NRTI

- K219E/Q/N/R are accessory TAMs that usually occur in combination with multiple other TAMs.

NNRTI

- Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. It does not significantly reduce DOR susceptibility.

Other

- V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility.
- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

- This virus is predicted to have intermediate-level reduced susceptibility to **RPV**. The use of the combination of CAB/**RPV** should be considered to be contraindicated.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC	AZT	D4T	DDI	FTC	3TC	TDF
K219Q	5	10	10	5	0	0	5

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR	EFV	ETR	NVP	RPV
Y181C	10	30	30	60	45